ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Revenue
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H had a revenue of 39.41M in the quarter ending Dec 31, 2024, with 0.00%. This bring the company's revenue in the last twelve months to 79.18M, Decreased 99.10%. In the fiscal year ending Dec 31, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H had annual revenue of 74.15M with 19109.59% growth.